Table 4.
Safety assessment for consolidation chemotherapy after adjuvant therapy in the entire cohort.
| Complications | Control group (n=137) |
Study group (n=100) |
P value |
|---|---|---|---|
| Hematologic toxicities | |||
| Neutropenia | |||
| Any grade | 95(69.34%) | 99(99.00%) | P<0.001 |
| Grade ≥3 | 17(12.41%) | 48(48.00%) | P<0.001 |
| Anemia | |||
| Any grade | 97(70.80%) | 100(100.00%) | P<0.001 |
| Grade ≥3 | 4(2.92%) | 23(23.00%) | P<0.001 |
| Thrombocytopenia | |||
| Any grade | 64(46.72%) | 67(67.00%) | P=0.002 |
| Grade ≥3 | 5(3.65%) | 13(13.00%) | P=0.007 |
| Gastrointestinal toxicities | |||
| Nausea | 59(43.07%) | 50(50.00%) | P=0.290 |
| Vomiting | 21(15.33%) | 24(24.00%) | P=0.093 |
| Abdominal pain | 11(8.03%) | 12(12.00%) | P=0.308 |
| Diarrhea | 70(51.09%) | 53(53.00%) | P=0.772 |
| Decreased appetite | 61(44.52%) | 55(55.00%) | P=0.111 |
| Constipation | 40(29.20%) | 35(35.00%) | P=0.343 |
| Other adverse events | |||
| Febrile neutropenia | 2(1.46%) | 6(6.00%) | P=0.073 |
| Fatigue | 42(30.66%) | 27(27.00%) | P=0.541 |
| Hepatocellular injury | 4(2.92%) | 9(9.00%) | P=0.042 |
| Renal failure | 1(0.73%) | 4(4.00%) | P=0.165 |
| Small bowel obstruction | 5(3.65%) | 2(2.00%) | P=0.702 |
| Infection | 2(1.46%) | 5(5.00%) | P=0.136 |
The bold values mean p value less than 0.05.